WO2012041031A1 - 一种用于哮喘的吸入性复方组合物 - Google Patents
一种用于哮喘的吸入性复方组合物 Download PDFInfo
- Publication number
- WO2012041031A1 WO2012041031A1 PCT/CN2011/070883 CN2011070883W WO2012041031A1 WO 2012041031 A1 WO2012041031 A1 WO 2012041031A1 CN 2011070883 W CN2011070883 W CN 2011070883W WO 2012041031 A1 WO2012041031 A1 WO 2012041031A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- procaterol
- receptor agonist
- drug
- composition according
- inhalation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Definitions
- the present invention relates to a combination composition, and more particularly to a combination composition comprising an inhaled corticosteroid in combination with a beta 2 receptor agonist.
- asthma asthma
- COPD Chronic Obstructive Pulmonary Disease
- inhaled corticosteroids including Fluticasone propionate, Budesonide, Ciclesonide, Momethasone foroate, also known as Mometasone, Beclomethasone dipropionate, and Triamcinolone acetonide.
- Beta 2 agonists or beta 2 receptor agonists commercially available beta 2 agonists include Albuterol sulfate or salbutamol Salbutamol sulphate), Procaterol hydrochloride, Fenotropol hydrogen: Fenoterol hydrobromide, Reproterol hydrochloride, Formoterol, Shike Terbutaline sulphate, Salmeterol xinafoate.
- Formoterol and Salmeterol are long acting beta 2 agonists (LABA, long acting beta2 agonists) with a duration of up to 12 hours and must be combined with inhaled steroids to improve symptoms in patients with moderate to severe persistent asthma. And lung function.
- LPA long acting beta 2 agonists
- FenoteroK AalbuteroK Terbutaline or Procaterol are short-acting and fast-acting ⁇ 2 receptor agonists.
- the duration of action is about 3 to 6 hours or 4 to 8 hours.
- the clinical application is mainly for the rapid release of emergency tracheal contraction symptoms. It can be used three to four times a day.
- Taiwanese publication No. 200303767 discloses that Formoterol's ultra-fine formula contains 0.003-0.192% w/v of (R, R)-( ⁇ )-formoterol fumaric acid Salt, a pharmaceutical composition for the treatment of respiratory and pulmonary diseases containing monomegetametone citrate disclosed in Taiwan Patent No. 329387. China CN1305380 Publication No.
- U.S. Patent No. 5,972,919 discloses that the molar ratio of the active ingredient Formoterol to the Budesonide component is 1: 4-1:70.
- Inhaled corticosteroids have been disclosed in U.S. Patent Nos. 6, 932, 962, 6, 799, 572, 6, 638, 495, 6, 962, 151, 7, 321, 059.
- the combination of drugs includes Budesonide, Fluticasone, Mometasone, Beclomethasone, Ciclesonide and other steroids, and beta-2 agonists use Fenoterol, Albuterol, Procaterol, Salmeterol and Formoterol.
- U.S. Patent Nos. 7, 244, 742, 7, 481, 995, 6, 596, 261 further disclose the addition of Ipratropium anti-acetylcholine drugs to a combination of inhaled steroids and a ⁇ 2 receptor agonist drug (Anticholinergics). ), but all of them are medicinal techniques, rather than the combination of aging, dose, and usage changes of the drug to be used in the present invention to improve clinical therapeutic efficacy.
- the above two methods of respiratory therapy using an oral ⁇ 2 receptor agonist drug in combination with an inhaled corticosteroid, or two drugs to produce a continuous aerosol treatment with a nebulizer, and the compound quantification of the present invention
- the inhalation or dry powder inhalation is different.
- the administration method of the aerosol machine with the inhalation solution is sick.
- the amount of the drug administered to the patient, and the dose of the drug administered by oral administration are much higher than the dose of the quantitative propellant or dry powder inhaler, and the average of 2 times a day.
- the control therapy differs from the blood concentration of the lower and one ambiguous drug provided by the eccentric therapy of the present invention.
- GINA's treatment guidelines adopt a stepwise up-and-down adjustment of the treatment concept, that is, according to the condition, adjust the dose-reduction method to control the patient's condition:
- a short-acting fast acting ⁇ 2 agonist (p2-agonist ) is given to relieve symptoms;
- Controlled treatment given a. low dose inhaled corticosteroids or b. leukotriene inhibitors.
- Symptoms a short-acting, rapid-acting beta 2 agonist ( p2-agonist ) at the onset; third-stage moderate patient:
- Controlled treatment Choose to administer a "low-dose inhaled corticosteroids with long-acting beta 2 agonists", b. high-dose inhaled corticosteroids, c. "low-dose inhaled corticosteroids with leukotrienes "” or d. "Low-dose inhaled corticosteroids with long-acting theophylline”.
- Dispelling symptoms a short-acting rapid acting beta 2 agonist (p2-agonist) at the time of attack; a fourth-stage severe patient:
- Controlled treatment Choose to give a. "high-dose inhaled corticosteroids with long-acting beta 2 agonists", b. leukotriene inhibitors, c. long-acting theophylline or selectively.
- Dispelling Symptoms A short-acting, rapid-acting beta 2 agonist (p2-agonist) at the time of attack; a severe acute episode of level 5:
- Controlled therapy Level 4 controlled treatment with oral corticosteroids or anti-IgE immunotherapy,
- Dispelling Symptoms Give a short-acting, rapid-acting beta 2 agonist ( p2-agonist ) at the time of onset;
- ⁇ 2 receptor agonist the mechanism of acute drug resistance, is caused by the ⁇ 2 receptor down regulation. It is also known that certain genotype patients are more likely to develop the onset of acute drug resistance during the course of treatment with a ⁇ 2 receptor agonist.
- composition as a main treatment for asthma, such as Budesonide with Formoterol fumarate, Fluticasone propionate with Salicol xinafoate, Fluticasone propionate with Formoterol fumarate, Ciclesonide with Formoterol fumarate, Momethasone furoate with Formoterol fumarate, Beclomethasone Mixing Formoterol fumarate or Fluticasone furoate with Vilanterol trifenatate, etc., the dosage form is mainly dry powder inhaler (DPI) or metered Dose Inhaler (MDI). These pharmaceutical compositions have become the current The main research and development direction.
- DPI dry powder inhaler
- MDI metered Dose Inhaler
- ⁇ 2 receptor agonists of such combination compositions are drugs that are administered twice daily for 24 hours, while Vilanterol trifenatate is administered once daily. .
- a patent for the use of a ⁇ 2 receptor agonist, Procaterol HC1, in combination with an inhaled corticosteroid, is disclosed in U.S. Patent Publication No. 6, 503, 537, 7, 387, 794, which is incorporated herein by reference.
- 7, 244, 414, 7, 658, 949, 7, 687, 073, 7, 694, 676, 7, 736, 628 are related to dry powder inhalers and 7, 172, 752 are combined powders
- 7, 550, 133 is a concentrated drug for inhalation
- 7, 109, 247 is a suspension of nanoparticles
- 6, 814, 953 is used for an aerosol device.
- HFA hydrofluoroalkanes
- the mechanism of this acute drug resistance may be related to the ⁇ 2 receptor agonist, which is related to the tracheal expansion effect caused by indirect consumption of some endogenous tracheal dilating substances in the body.
- the concentration of cyclic adenosine monophosphate (cAMP) in the mouth is increased, and cAMP is acted upon by the protein thorax, which produces a series of reactions that promote tracheal expansion. Therefore, during the large dose of ⁇ 2 receptor agonist, the intrinsic tracheal dilatation material is also consumed, and when the self-replenishment of such substances in the body is lower than the consumption rate, it is sufficient to induce acute drug resistance.
- cAMP cyclic adenosine monophosphate
- One concept of the present invention provides an inhaled combination composition comprising an effective amount of a ⁇ 2 receptor agonist in combination with an effective amount of a corticosteroid drug, if necessary, with a pharmaceutically acceptable carrier.
- Another concept of the present invention provides an inhalation propellant or dry powder inhaler composition comprising an effective amount of a ⁇ 2 receptor agonist in combination with an effective amount of a corticosteroid drug, if necessary, with a pharmaceutically acceptable carrier.
- the ⁇ 2 receptor agonist is selected from the group consisting of Albuterol, Fenoterol, Procaterol, Terbutaline and its base At least one of the drug Albuterol sulfate, Procaterol HC1, Fenoterol hydrobromide, and Terbutaline sulphate.
- the corticosteroid drug is selected from the group consisting of Budesonide, Fluticasone, Mometasone, Ciclesonide, Beclomethasone, and Deflaming Pine. (Triamcinolone), Tipredane and other drugs and its salt form Fluticasone propionate, Beclomethasone dipropionate, and Triamcinolone Acetonide one.
- Yet another concept of the present invention provides a compound composition for asthma, one of the purposes of which is to use Bipolar control treatment for diseases such as asthma or chronic lung obstruction.
- Bipolar therapy is the preferred mode of treatment, that is, more daily doses are more severe, and the disease is less likely to be administered or administered less, giving patients time to recover the intrinsic tracheal expansion in the body. substance.
- polar therapy also provides treatment for patients with asthma or chronic lung obstruction if necessary. Therefore, the polar therapy has a better selectivity for the long-acting ⁇ 2 receptor agonist compound administered by the patient than the current two-day controlled administration mode.
- albumin nasal cavity induction (OVA challenge i.n.) albumin nasal cavity is induced again to ensure that the mouse is allergic
- G 2 times a day of intratracheal administration (I.T.) 7 days after the tracheal hypercontraction response (AHR), and then through the lung respiratory tract lavage (BALF) to observe the number and type of lung immune cells (I.T. 7 Days Twice daily)
- AHR The tracheal hypercontraction response (AHR) was measured once daily after intratracheal administration (LT.), and the number and type of lung immune cells were observed by pulmonary lavage (BALF) (LT. 1 Day AHR BALF)
- I Quantitative immunoassay (IgE ELISA assay), enzyme-binding immunosorbent assay (ELISA) to measure the concentration of immunoglobulin E in mice to confirm that the allergic constitution of mice has been established.
- Figure 2 Dose-effect response of the long-acting beta 2 receptor agonist Salmeterol.
- A Normal control group B: Asthma control group
- A Normal control group B: Asthma control group
- A Normal control group B: Asthma control group
- mice were divided into groups according to the control group and the drug administration group.
- the control group included a normal control group in which non-sensitized mice were administered saline (without drugs), and sensitized mice were not administered with the drug-treated asthma control group.
- the drug-administered group was divided into different doses of different ⁇ 2 agonists, different dose frequency groups, and ⁇ 2 receptor agonists combined with corticosteroid combination drugs in different doses and frequency groups.
- mice to be sensitized were injected with intraperitoneal albumin (OVA) three times at intervals of 10 days, and blood was collected on the 24th day. After IgE was confirmed to confirm allergic constitution, the nasal cavity was re-administered with albumin on the 26th day, and the trachea was started on the 30th day. Dosing, once-dose and once or twice daily in the 7-day dosing group, after the last administration, incision of the tracheal intubation, instrumentation of acetylcholine (MCh)-induced tracheal contraction data collection data.
- MCh acetylcholine
- Short-acting beta 2 agonists are used alone to relieve tracheal dilating agents in emergency symptoms for patients at all levels relative to the models listed in the GINA guidelines. If the administration of short-acting ⁇ 2 agonists is changed, a combination of short-acting ⁇ 2 agonists and corticosteroids should be used as a separate method. That is, using the combination composition of the "inhaled corticosteroid drug in combination with a short-acting rapid acting ⁇ 2 receptor agonist" of the present invention to provide emergency patients at all levels, and to relieve the symptoms of an emergency with such a tracheal dilator .
- the oral corticosteroids need to be added to further control the condition, indicating that the patient may need additional corticosteroids to help the patient recover the tracheal expansion function.
- the short-acting rapid action of the corticosteroids of the present invention is a compound of the ⁇ 2 receptor agonist, which can be used as an emergency for the onset of all grades of asthma patients, providing a better choice.
- These additional corticosteroids can help the patient to relieve the disease by its anti-inflammatory effect.
- a combination composition formulated according to an embodiment of the present invention using a medium- and short-acting ⁇ 2 receptor agonist Procatero K FenoteroK Terbutaline or Albuterol and a salt-based drug thereof, such as a single inhalation method for inhalation, the tracheal dilatation effect is about 6 ⁇ 8 hours. If used 3 to 4 times a day, although acute drug resistance occurs, only the retention of the dilated tracheal effect will decrease for 3 to 4 hours. Inhaled corticosteroid Budesonide is used, and the polarity is used before bedtime and after getting up. The efficacy can be restored to 6-8 hours.
- the symptomatic effect of the compound composition of the present invention can be used to control the condition of the patient for a long time.
- the ⁇ 2 receptors such as Procaterol HC1, ProcateroK Albuterol, Albuterol sulfate, Fenoterol, Fenoterol hydrobromide, etc., which have a pharmacodynamic effect of 3 to 8 hours, are inhaled corticosteroid drugs, such as Budesonide.
- the weight ratio of the ⁇ 2 receptor agonist to these inhaled corticosteroid drugs is about 1: 2 w/w. /c ⁇ l : 70w/w%, preferably in the range of 1: 5 w/w% to 1: 60 w/w %.
- inhaled corticosteroids Procaterol, Albuterol, Terbutaline, Fenoterol is a compound of its base, which is acutely associated with anti-inflammatory and slowing down of ⁇ 2 agonists.
- Drug-resistant inhaled corticosteroids Relative to a single drug containing only a ⁇ 2 receptor agonist, it provides an urgent relief effect at the onset of the disease, which helps the recovery of the disease and reduces the number of serious episodes over a long period of time.
- the invention relates to a polar administration dosage form of an inhaled ⁇ 2 receptor agonist combined with a corticosteroid compound compound, and can select a hydrofluorocarbon propellant quantitative propellant (HFA MDI ) or a dry powder inhaler ( DPI).
- HFA MDI hydrofluorocarbon propellant quantitative propellant
- DPI dry powder inhaler
- pharmaceutically acceptable carrier is an excipient required for the preparation of a combination of a ⁇ 2 receptor agonist and a corticosteroid combination, so that it does not cause adverse reactions, allergies or other effects to animals or humans. Inappropriate reaction.
- the carrier or excipient may also include a suitable amount of a surfactant, a solvent, a suspending agent, and a propellant for a safe formulation.
- the formulation of the hydrofluorocarbon propellant quantitative projectile inhaler (HFA MDI) used in the present invention is usually prepared by using 1,1,1, 2 tetrafluoroethane (HFA 134a, HFC 134a) or 1, 1 , 1 , 2 , 3, 3, 3-heptafluoropropane (Heptafluoro-n-propane, HFC 227ea, HFC 227, HFA 227), and a quantitative ejecting preparation in which HFA 134a and HFA 227 are used, if necessary.
- the dry powder inhaler can be optionally filled into the capsule with a carrier-free main ingredient drug via a single-dose inhaler, or a preparation containing lactose as a carrier via a single-dose inhaler.
- Activity test method :
- mice were divided into normal control group and Ova control group, each group consisted of 2 to 28 (the number of pre-dose exploration stages was small, and the confirmation after repeated dose confirmation) The number of experiments was only large. The drinking water and feed supply of each group were the same.
- OVA ovalbumin
- OVA ovalbumin
- Normal control group not sensitized and administered saline.
- the sensitized asthma control group also administered saline but did not receive medication. Three days before the administration, OVA was given continuously in the nasal cavity to strengthen the hypersensitivity.
- mice Each group of mice was divided into different drugs and different doses. Each group was divided into different administration groups according to one dose and one dose (qd) or two doses (bid) for 7 days. Mixing saline or saline solution The combination of Procaterol and Budesonide is directly administered to the ' throat'.
- Procaterol 1.0 g/kg 2 times a day X 7 days 19 (B19+P1 )
- Budesonide 180.0 g / kg take a dose of 10 West Procaterol 10.0 g / kg
- Budesonide 200.0 g/kg take one day 1 time X 7 days 3 Westself Procaterol 12.5 g/kg
- Budesonide 225.0 g/kg take 2 times a day X 7 days 2 Xiji Procaterol 12.5 g/kg
- the trachea of the mice was dissected under anesthesia, and the instrument for measuring the resistance of the trachea was stimulated with a Methacholine (MCh) aerosol and the lung tracheal resistance was tested with a SCIREQ FlexiVent.
- MCh Methacholine
- the components in which the components were mixed and dissolved in the hydrofluorocarbons were prepared as a quantitative inhalation inhaler, either directly in the capsule or as a dry powder inhaler via a single dose inhaler.
- An inhaled combination composition comprising an effective amount of a ⁇ 2 receptor agonist in combination with an effective amount of a corticosteroid drug, if necessary, with a pharmaceutically acceptable carrier.
- ⁇ 2 receptor agonist is selected from the group consisting of Albuterol, Fenoterol, and Procacrizu ( Procaterol), terbutaline and its base drug Albuterol sulfate, Procaterol HC1, Fenoterol hydrobromide, and At least one of terbutaline sulphate.
- corticosteroid drug is selected from the group consisting of Budesonide, Fluticasone, Mometasone, and ciclesonide.
- Budesonide Fluticasone, Mometasone, and ciclesonide.
- Beclomethasone Triamcinolone, and its salt form morphine Fluticasone propionate
- Beclomethasone dipropionate and Cinnamomum trifoliate (Triamcinolone Acetonide ) at least one of them.
- An inhalation propellant composition comprising a pharmaceutically acceptable carrier; and an effective amount of a beta 2 receptor agonist in combination with an effective amount of a corticosteroid.
- ⁇ 2 receptor agonist is selected from the group consisting of Albuterol, Fenoterol, Prouka Procaterol, Terbutaline and its salt-based drug Albuterol sulfate, Procaterol HC1, Fenoterol hydrobromide And at least one of Terbutaline sulphate.
- the corticosteroid drug is selected from the group consisting of Budesonide, Fluticasone, Mometasone, and a ring.
- composition according to any one of embodiments 6-10, wherein the pharmaceutically acceptable carrier optionally employs a hydrofluorocarbon propellant, a surfactant, a solvent, a suspending agent or a milk. sugar.
- An inhalable dry powder composition comprising a pharmaceutically acceptable carrier; and an effective amount of a [beta]2 receptor agonist in combination with an effective amount of a corticosteroid drug.
- ⁇ 2 receptor agonist is selected from the group consisting of Albuterol, Fenoterol, Procacal Procaterol, terbutaline and its salt-based drug Albuterol sulfate, Procaterol HC1, Fenoterol hydrobromide, At least one of Terbutaline sulphate.
- the corticosteroid drug is selected from the group consisting of Budesonide, Fluticasone, Mometasone, and Cycloaddin.
- Ciclesonide, Beclomethasone, Triamcinolone, and its salt-based morphological drugs and their salt form morphological drugs Fluticasone propionate, Beclomethasone dipropionate And at least one of Triamcinolone Acetonide.
- composition according to any one of embodiments 13-17, wherein the pharmaceutically acceptable carrier is optionally lactose.
- the corticosteroid drug is Budesonide, Fluticasone , Mometasone, Ciclesonide, Beclomethasone, Triamcinolone, and its salt form morphine Fluticasone propionate, propionate chlorinated Beclomethasone dipropionate and at least one of Triamcinolone Acetonide.
- composition according to any one of the preceding embodiments, wherein the ⁇ 2 receptor agonist is Procaterol, the corticosteroid drug is selected from the group consisting of Budesonide and fluticasone.
- the corticosteroid drug is selected from the group consisting of Budesonide and fluticasone.
- Fluticasone Fluticasone
- Mometasone Ring Ciclesonide
- Beclomethasone Triamcinolone
- Triamcinolone Triamcinolone
- At least one of Triamcinolone Acetonide At least one of Triamcinolone Acetonide.
- composition according to any one of the preceding embodiments, wherein the ⁇ 2 receptor agonist is selected from the group consisting of Albuterol, the corticosteroid drug is selected from the group consisting of Budesonide and fluticasone.
- the ⁇ 2 receptor agonist is selected from the group consisting of Albuterol
- the corticosteroid drug is selected from the group consisting of Budesonide and fluticasone.
- Flucasone Mometasone
- Ciclesonide Ciclesonide
- Beclomethasone Triamcinolone
- Triamcinolone Triamcinolone
- C At least one of Beclomethasone dipropionate and Triamcinolone Acetonide.
- Mometasone Ciclesonide, Beclomethasone, Triamcinolone and its salt form morphological drug Fluticasone propionate, Beclomethasone dipropionate, and Triamcinolone Acetonide are at least one of them.
- composition of any of embodiments 1-12, wherein the hydrofluorocarbon propellant is selected from the group consisting of HFA 134a or HFA 227.
- composition of any of embodiments 1-12, wherein the hydrofluorocarbon propellant is a combination of HFA 134a and HFA 227.
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ607900A NZ607900A (en) | 2010-09-28 | 2011-02-01 | Compound composition for inhalation used for treating asthma |
SG2013016621A SG188426A1 (en) | 2010-09-28 | 2011-02-01 | Compound composition for inhalation used for treating asthma |
EP11827927.2A EP2626065A4 (en) | 2010-09-28 | 2011-02-01 | INHIBITABLE COMPOSITION COMPOSITION FOR THE TREATMENT OF ASTHMA |
KR1020137010636A KR101475262B1 (ko) | 2010-09-28 | 2011-02-01 | 천식 치료에 사용되는 흡입용 복합 조성물 |
AU2011307899A AU2011307899B2 (en) | 2010-09-28 | 2011-02-01 | Compound composition for inhalation used for treating asthma |
US13/876,387 US8877740B2 (en) | 2010-09-28 | 2011-02-01 | Compound composition for inhalation used for treating asthma |
CA2811345A CA2811345C (en) | 2010-09-28 | 2011-02-01 | Compound composition for inhalation used for treating asthma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010502339.3A CN102416179B (zh) | 2010-09-28 | 2010-09-28 | 用于哮喘的吸入性复方组合物 |
CN201010502339.3 | 2010-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012041031A1 true WO2012041031A1 (zh) | 2012-04-05 |
Family
ID=45891864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/070883 WO2012041031A1 (zh) | 2010-09-28 | 2011-02-01 | 一种用于哮喘的吸入性复方组合物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8877740B2 (zh) |
EP (1) | EP2626065A4 (zh) |
KR (1) | KR101475262B1 (zh) |
CN (1) | CN102416179B (zh) |
AU (1) | AU2011307899B2 (zh) |
CA (1) | CA2811345C (zh) |
HK (1) | HK1169334A1 (zh) |
MY (1) | MY179794A (zh) |
NZ (1) | NZ607900A (zh) |
SG (1) | SG188426A1 (zh) |
WO (1) | WO2012041031A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110025578A (zh) * | 2019-04-10 | 2019-07-19 | 深圳市新阳唯康科技有限公司 | 一种治疗哮喘类肺部疾病的共无定形粉末及其制备方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR970020116A (ko) * | 1995-09-19 | 1997-05-28 | 노보루 아까사까 | 인간 뇨 트립신 억제제 제제 및 그의 제조방법 |
TWI399202B (zh) * | 2011-03-17 | 2013-06-21 | Intech Biopharm Ltd | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 |
CN104069497A (zh) * | 2014-06-27 | 2014-10-01 | 东莞市凯法生物医药有限公司 | 一种降低药物耐受性的组合物、方法及其应用 |
GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
CN115463117A (zh) * | 2022-09-14 | 2022-12-13 | 四川普锐特药业有限公司 | 一种递送效率高的布地奈德沙丁胺醇复方雾化吸入混悬液及其制备方法 |
Citations (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270305A (en) | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
US5674472A (en) | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Canisters containing aerosol formulations containing P134a and fluticasone propionate |
US5674860A (en) | 1991-12-18 | 1997-10-07 | Astra Aktiebolag | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders |
US6123924A (en) | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
US6143277A (en) | 1995-04-14 | 2000-11-07 | Glaxo Wellcome Inc. | Metered dose inhaler for salmeterol |
US6253762B1 (en) | 1995-04-14 | 2001-07-03 | Glaxo Wellcome Inc. | Metered dose inhaler for fluticasone propionate |
CN1305380A (zh) | 1998-06-11 | 2001-07-25 | 阿斯特拉曾尼卡有限公司 | 含有福莫特罗和布地奈德的组合物在预防和治疗急性气喘疾病中的应用 |
US6315173B1 (en) | 1996-12-27 | 2001-11-13 | Smithkline Beecham Corporation | Valve for aerosol container |
US6503537B2 (en) | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
CN1425378A (zh) * | 2003-01-14 | 2003-06-25 | 鲁南制药股份有限公司 | 治疗支气管哮喘的组合物 |
US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
US6638495B2 (en) | 1997-09-29 | 2003-10-28 | Nektar Therapeutics | Stabilized preparation for use in metered dose inhalers |
US6641800B1 (en) | 1991-09-25 | 2003-11-04 | Fisons Ltd. | Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane |
US20040101483A1 (en) | 2001-03-30 | 2004-05-27 | Rudi Muller-Walz | Medical aerosol formulations |
US20040105819A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Respiratory drug condensation aerosols and methods of making and using them |
US6799572B2 (en) | 2000-12-22 | 2004-10-05 | Chrysalis Technologies Incorporated | Disposable aerosol generator system and methods for administering the aerosol |
US6814953B2 (en) | 2001-04-17 | 2004-11-09 | Dey L.P. | Bronchodilating compositions and methods |
US20040241103A1 (en) | 2002-09-10 | 2004-12-02 | 3M Innovative Properties Company | Pharmaceutical aerosol compositions |
US20050085445A1 (en) | 2002-02-07 | 2005-04-21 | Muller Bernd W. | Cyclodextrines for use as suspension stabilizers in pressure-liquefied propellants |
US6932962B1 (en) | 1994-12-22 | 2005-08-23 | Astrazeneca Ab | Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides |
US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
US7067502B2 (en) | 1999-03-03 | 2006-06-27 | Novartis Ag | Combinations of formoterol and mometasone furoate for asthma |
US7109247B2 (en) | 2003-05-30 | 2006-09-19 | 3M Innovative Properties Company | Stabilized particle dispersions containing nanoparticles |
US7172752B2 (en) | 2000-10-06 | 2007-02-06 | Orion Corporation | Combination particles for the treatment of asthma |
US7244414B2 (en) | 2001-08-23 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing inhalable powders |
US7244742B2 (en) | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
US20070196285A1 (en) | 2005-12-21 | 2007-08-23 | Meda Pharma Gmbh & Co. Kg | Novel combination of anticholinergics - B2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases |
US7267813B2 (en) | 2000-10-06 | 2007-09-11 | Orion Corporation | Inhalation particles incorporating a combination of two or more active ingredients |
US7321059B2 (en) | 2001-10-19 | 2008-01-22 | Glaxo Group Limited | Compounds for use as surfactants |
CN101124198A (zh) * | 2004-12-17 | 2008-02-13 | 希普拉有限公司 | 药物化合物和组合物 |
US20080066741A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US20080078382A1 (en) | 2006-09-20 | 2008-04-03 | Lemahieu Edward | Methods and Systems of Delivering Medication Via Inhalation |
US20080279788A1 (en) | 2005-10-28 | 2008-11-13 | Hans Hermann Weil | Propellant for Dosing Aerosols Comprising Packagings |
US7459146B2 (en) | 2003-05-30 | 2008-12-02 | 3M Innovative Properties Company | Stabilized aerosol dispersions |
US7481995B2 (en) | 1998-04-03 | 2009-01-27 | University College Cardiff Consultants Limited | Aerosol composition |
US20090047336A1 (en) | 2007-08-17 | 2009-02-19 | Hong Kong Baptist University | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation |
CN101433527A (zh) * | 2007-11-13 | 2009-05-20 | 天津金耀集团有限公司 | 植物胶囊在粉雾剂中的应用 |
US20090274771A1 (en) | 2007-10-25 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
US20100008997A1 (en) | 2007-10-25 | 2010-01-14 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
US7658949B2 (en) | 2004-10-01 | 2010-02-09 | Boehringer Ingelheim International Gmbh | Surface modification of lactose excipient for use in powders for inhalation |
US7694676B2 (en) | 2005-04-22 | 2010-04-13 | Boehringer Ingelheim Gmbh | Dry powder inhaler |
US7736628B2 (en) | 2004-10-01 | 2010-06-15 | Boehringer Ingelheim International Gmbh | Powdered inhalants based on modified lactose mixtures as excipient |
TWI329837B (en) | 2003-10-10 | 2010-09-01 | Dell Products Lp | Information handling system and computer system having one or more central processing units operative with main memory and method of updating a bios |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1298699A (zh) * | 2000-02-15 | 2001-06-13 | 丛繁滋 | 速效平喘气雾剂及其制备方法 |
CN1353980A (zh) * | 2001-11-14 | 2002-06-19 | 丛繁滋 | 速效平喘气雾剂及其制备方法 |
EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
GB0614621D0 (en) * | 2006-07-24 | 2006-08-30 | 3M Innovative Properties Co | Metered dose dispensers |
-
2010
- 2010-09-28 CN CN201010502339.3A patent/CN102416179B/zh active Active
-
2011
- 2011-02-01 NZ NZ607900A patent/NZ607900A/en not_active IP Right Cessation
- 2011-02-01 SG SG2013016621A patent/SG188426A1/en unknown
- 2011-02-01 MY MYPI2013000680A patent/MY179794A/en unknown
- 2011-02-01 KR KR1020137010636A patent/KR101475262B1/ko active IP Right Grant
- 2011-02-01 EP EP11827927.2A patent/EP2626065A4/en not_active Withdrawn
- 2011-02-01 AU AU2011307899A patent/AU2011307899B2/en not_active Ceased
- 2011-02-01 CA CA2811345A patent/CA2811345C/en not_active Expired - Fee Related
- 2011-02-01 WO PCT/CN2011/070883 patent/WO2012041031A1/zh active Application Filing
- 2011-02-01 US US13/876,387 patent/US8877740B2/en not_active Expired - Fee Related
-
2012
- 2012-10-16 HK HK12110225.2A patent/HK1169334A1/zh not_active IP Right Cessation
Patent Citations (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE40045E1 (en) | 1989-09-08 | 2008-02-05 | Glaxo Group Limited | Medicaments |
US5270305A (en) | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
US6641800B1 (en) | 1991-09-25 | 2003-11-04 | Fisons Ltd. | Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane |
US6123924A (en) | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
US6251368B1 (en) | 1991-12-12 | 2001-06-26 | Glaxo Group Limited | Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant |
US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
US5674472A (en) | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Canisters containing aerosol formulations containing P134a and fluticasone propionate |
US5674860A (en) | 1991-12-18 | 1997-10-07 | Astra Aktiebolag | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders |
US5972919A (en) | 1991-12-18 | 1999-10-26 | Astra Aktiebolag | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof |
US6932962B1 (en) | 1994-12-22 | 2005-08-23 | Astrazeneca Ab | Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides |
US6253762B1 (en) | 1995-04-14 | 2001-07-03 | Glaxo Wellcome Inc. | Metered dose inhaler for fluticasone propionate |
US6143277A (en) | 1995-04-14 | 2000-11-07 | Glaxo Wellcome Inc. | Metered dose inhaler for salmeterol |
US6546928B1 (en) | 1995-04-14 | 2003-04-15 | Smithkline Beecham Corporation | Metered dose inhaler for fluticasone propionate |
US6524555B1 (en) | 1995-04-14 | 2003-02-25 | Smithkline Beecham Corp. | Metered dose inhaler for salmeterol |
US6315173B1 (en) | 1996-12-27 | 2001-11-13 | Smithkline Beecham Corporation | Valve for aerosol container |
US6510969B2 (en) | 1996-12-27 | 2003-01-28 | Smithkline Beecham Corporation | Valve for aerosol container |
US7687073B2 (en) | 1997-03-20 | 2010-03-30 | Schering Corporation | Preparation of powder agglomerates |
US7387794B2 (en) | 1997-03-20 | 2008-06-17 | Schering Corporation | Preparation of powder agglomerate |
US6503537B2 (en) | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
US6638495B2 (en) | 1997-09-29 | 2003-10-28 | Nektar Therapeutics | Stabilized preparation for use in metered dose inhalers |
US7481995B2 (en) | 1998-04-03 | 2009-01-27 | University College Cardiff Consultants Limited | Aerosol composition |
CN1305380A (zh) | 1998-06-11 | 2001-07-25 | 阿斯特拉曾尼卡有限公司 | 含有福莫特罗和布地奈德的组合物在预防和治疗急性气喘疾病中的应用 |
US7067502B2 (en) | 1999-03-03 | 2006-06-27 | Novartis Ag | Combinations of formoterol and mometasone furoate for asthma |
US20060054166A1 (en) | 1999-11-05 | 2006-03-16 | Pari Gmbh Spezialisten Fur Effektive Inhalation | Inhalation nebulizer |
US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
US7172752B2 (en) | 2000-10-06 | 2007-02-06 | Orion Corporation | Combination particles for the treatment of asthma |
US7267813B2 (en) | 2000-10-06 | 2007-09-11 | Orion Corporation | Inhalation particles incorporating a combination of two or more active ingredients |
US6799572B2 (en) | 2000-12-22 | 2004-10-05 | Chrysalis Technologies Incorporated | Disposable aerosol generator system and methods for administering the aerosol |
US20040101483A1 (en) | 2001-03-30 | 2004-05-27 | Rudi Muller-Walz | Medical aerosol formulations |
US6814953B2 (en) | 2001-04-17 | 2004-11-09 | Dey L.P. | Bronchodilating compositions and methods |
US7244414B2 (en) | 2001-08-23 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing inhalable powders |
US7321059B2 (en) | 2001-10-19 | 2008-01-22 | Glaxo Group Limited | Compounds for use as surfactants |
US20050085445A1 (en) | 2002-02-07 | 2005-04-21 | Muller Bernd W. | Cyclodextrines for use as suspension stabilizers in pressure-liquefied propellants |
US7244742B2 (en) | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
US20040241103A1 (en) | 2002-09-10 | 2004-12-02 | 3M Innovative Properties Company | Pharmaceutical aerosol compositions |
US20090258075A1 (en) | 2002-11-26 | 2009-10-15 | Alexza Pharmaceuticals, Inc. | Respiratory Drug Condensation Aerosols and Methods of Making and Using Them |
US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US20040105819A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Respiratory drug condensation aerosols and methods of making and using them |
CN1425378A (zh) * | 2003-01-14 | 2003-06-25 | 鲁南制药股份有限公司 | 治疗支气管哮喘的组合物 |
US7459146B2 (en) | 2003-05-30 | 2008-12-02 | 3M Innovative Properties Company | Stabilized aerosol dispersions |
US7109247B2 (en) | 2003-05-30 | 2006-09-19 | 3M Innovative Properties Company | Stabilized particle dispersions containing nanoparticles |
TWI329837B (en) | 2003-10-10 | 2010-09-01 | Dell Products Lp | Information handling system and computer system having one or more central processing units operative with main memory and method of updating a bios |
US7736628B2 (en) | 2004-10-01 | 2010-06-15 | Boehringer Ingelheim International Gmbh | Powdered inhalants based on modified lactose mixtures as excipient |
US7658949B2 (en) | 2004-10-01 | 2010-02-09 | Boehringer Ingelheim International Gmbh | Surface modification of lactose excipient for use in powders for inhalation |
CN101124198A (zh) * | 2004-12-17 | 2008-02-13 | 希普拉有限公司 | 药物化合物和组合物 |
US7694676B2 (en) | 2005-04-22 | 2010-04-13 | Boehringer Ingelheim Gmbh | Dry powder inhaler |
US20080279788A1 (en) | 2005-10-28 | 2008-11-13 | Hans Hermann Weil | Propellant for Dosing Aerosols Comprising Packagings |
US20070196285A1 (en) | 2005-12-21 | 2007-08-23 | Meda Pharma Gmbh & Co. Kg | Novel combination of anticholinergics - B2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases |
US20080078382A1 (en) | 2006-09-20 | 2008-04-03 | Lemahieu Edward | Methods and Systems of Delivering Medication Via Inhalation |
US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US20080066741A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US20090047336A1 (en) | 2007-08-17 | 2009-02-19 | Hong Kong Baptist University | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation |
US20100008997A1 (en) | 2007-10-25 | 2010-01-14 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
US20090274771A1 (en) | 2007-10-25 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
CN101433527A (zh) * | 2007-11-13 | 2009-05-20 | 天津金耀集团有限公司 | 植物胶囊在粉雾剂中的应用 |
Non-Patent Citations (5)
Title |
---|
ALBERS M; SCHERMER T; VAN WC: "Airflow limitation as a screening tool: too relevant to ignore, too conspicuous to apply?", CHEST, vol. 128, no. 4, 2005, pages 1898 - 900 |
CHEST, vol. 128, no. 4, October 2005 (2005-10-01) |
CHIESI, NEW ENGLAND JOURNAL OF MEDICINE, vol. 356, 2007, pages 2040 - 2052 |
PAPI, A.; G. W. CANONICA ET AL.: "Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma", NEW ENGLAND JOURNAL OF MEDICINE, vol. 356, no. 20, 2007, pages 2040 - 2052 |
See also references of EP2626065A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110025578A (zh) * | 2019-04-10 | 2019-07-19 | 深圳市新阳唯康科技有限公司 | 一种治疗哮喘类肺部疾病的共无定形粉末及其制备方法 |
CN110025578B (zh) * | 2019-04-10 | 2021-06-15 | 深圳市新阳唯康科技有限公司 | 一种治疗哮喘类肺部疾病的共无定形粉末及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
HK1169334A1 (zh) | 2013-01-25 |
NZ607900A (en) | 2014-08-29 |
MY179794A (en) | 2020-11-14 |
CA2811345A1 (en) | 2012-04-05 |
CA2811345C (en) | 2015-08-11 |
EP2626065A4 (en) | 2014-03-12 |
KR101475262B1 (ko) | 2014-12-22 |
AU2011307899B2 (en) | 2015-03-12 |
CN102416179B (zh) | 2014-05-07 |
SG188426A1 (en) | 2013-04-30 |
US20140031324A1 (en) | 2014-01-30 |
US8877740B2 (en) | 2014-11-04 |
CN102416179A (zh) | 2012-04-18 |
AU2011307899A1 (en) | 2013-04-04 |
KR20140032936A (ko) | 2014-03-17 |
EP2626065A1 (en) | 2013-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2745064T3 (es) | Formulación superfina de formoterol | |
US5642728A (en) | System for dispensing pharmaceutically active compounds | |
SI9200403A (en) | New combination of a bronchodilator and a steroidal antiinflammatory drug for treatment of respiratory disorders as well as its use and preparation thereof | |
US20210077382A1 (en) | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions | |
IT9048260A1 (it) | Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione. | |
CN103501781B (zh) | 吡咯糖用于治疗心动过速的用途 | |
JP2016519160A (ja) | 3つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム | |
WO2012041031A1 (zh) | 一种用于哮喘的吸入性复方组合物 | |
CN107998109A (zh) | 药物组合物 | |
ES2319887T3 (es) | Formulacion superfina de salmeterol. | |
CN103476412B (zh) | 用于改善呼吸系统疾病患者睡眠质量的阿地铵 | |
Hsieh et al. | Comparative efficacy and tolerability of beclomethasone/formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients | |
TWI495466B (zh) | 用於氣喘之吸入性複方組合物 | |
EA015353B1 (ru) | Применение солей тиотропия для лечения персистирующей астмы средней тяжести | |
JP6415536B2 (ja) | ブデソニドおよびフォルモテロールを含む医薬組成物 | |
TWI253930B (en) | Novel combination of loteprednol and beta2 adrenoceptor agonists | |
Thamby et al. | Retrospective studies on drug utilization patterns of asthmatics in a Government hospital in Kedah, Malaysia | |
TW200922600A (en) | DHEAS inhalation compositions | |
Zanen et al. | Targeting the lungs with therapeutic aerosols | |
ES2232769T3 (es) | Composicion farmaceutica que comprende salmeterol y budesonida para el tratamiento de trastornos respiratorios. | |
US20220054509A1 (en) | Methods of treatment for disease from coronavirus exposure | |
Salazar | Patient History/Case Study | |
Sadik | The young person with asthma | |
JP2010503623A (ja) | 慢性疲労症候群及び神経変性疾患の治療用組成物及び治療方法 | |
LAUBE | Targeting the Lungs with Therapeutic Aerosols |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11827927 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013500471 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2811345 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011307899 Country of ref document: AU Date of ref document: 20110201 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011827927 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137010636 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13876387 Country of ref document: US |